|
1
|
Matthay KK, Maris JM, Schleiermacher G,
Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat
Rev Dis Primers. 2:160782016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall GM, Carter DR, Cheung BB, Liu T,
Mateos MK, Meyerowitz JG and Weiss WA: The prenatal origins of
cancer. Nat Rev Cancer. 14:277–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takahashi Y, Sipp D and Enomoto H: Tissue
interactions in neural crest cell development and disease. Science.
341:860–863. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheung NK and Dyer MA: Neuroblastoma:
Developmental biology, cancer genomics and immunotherapy. Nat Rev
Cancer. 13:397–411. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bergman AM, Pinedo HM and Peters GJ:
Determinants of resistance to 2′,2′-difluorodeoxycytidine
(gemcitabine). Drug Resist Updat. 5:19–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis CS, Voelkel-Johnson C and Smith CD:
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells
by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget.
7:60181–60192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eriksson S and Martin DW Jr:
Ribonucleotide reductase in cultured mouse lymphoma cells. Cell
cycle-dependent variation in the activity of subunit protein M2. J
Biol Chem. 256:9436–9440. 1981.PubMed/NCBI
|
|
10
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
|
11
|
Itoi T, Sofuni A, Fukushima N, Itokawa F,
Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A and Kasuya K:
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment
biopsies obtained from unresectable pancreatic carcinomas. J
Gastroenterol. 42:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung CP, Motwani MV and Schwartz GK:
Flavopiridol increases sensitization to gemcitabine in human
gastrointestinal cancer cell lines and correlates with
down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer
Res. 7:2527–2536. 2001.PubMed/NCBI
|
|
14
|
Brodeur GM, Pritchard J, Berthold F,
Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE,
Favrot M, Hedborg F, et al: Revisions of the international criteria
for neuroblastoma diagnosis, staging and response to treatment.
Prog Clin Biol Res. 385:363–369. 1993.
|
|
15
|
Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang
Y, Feng T, Wu J and Liu X: Sphingosine-1-phosphate induced
epithelial-mesenchymal transition of hepatocellular carcinoma via
an MMP-7/syndecan-1/TGF-β autocrine loop. Oncotarget.
7:63324–63337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reece SY and Seyedsayamdost MR: Long-range
proton-coupled electron transfer in the Escherichia coli class Ia
ribonucleotide reductase. Essays Biochem. 61:281–292. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pai CC and Kearsey SE: A critical balance:
dNTPs and the maintenance of genome stability. Genes. 8:pii: E57.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui JQ, Shi YF, Zhou HJ and Li JQ: The
changes of gene expression profiles in hydatidiform mole and
choriocarcinoma with hyperplasia of trophoblasts. Int J Gynecol
Cancer. 14:984–997. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okamura H, Kamei T, Sakuma N, Hanai N and
Ishihara T: Ribonucleotide reductase immunoreactivity in
adenocarcinoma cells and malignant or reactive mesothelial cells in
serous effusions. Acta Cytol. 47:209–215. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Juhasz A, Vassilakos A, Chew HK, Gandara D
and Yen Y: Analysis of ribonucleotide reductase M2 mRNA levels in
patient samples after GTI-2040 antisense drug treatment. Oncol Rep.
15:1299–1304. 2006.PubMed/NCBI
|
|
21
|
Morikawa T, Hino R, Uozaki H, Maeda D,
Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of
ribonucleotide reductase M2 subunit in gastric cancer and effects
of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morikawa T, Maeda D, Kume H, Homma Y and
Fukayama M: Ribonucleotide reductase M2 subunit is a novel
diagnostic marker and a potential therapeutic target in bladder
cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mannargudi MB and Deb S: Clinical
pharmacology and clinical trials of ribonucleotide reductase
inhibitors: Is it a viable cancer therapy? J Cancer Res Clin Oncol.
143:1499–1529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duxbury MS, Ito H, Benoit E, Zinner MJ,
Ashley SW and Whang EE: Retrovirally mediated RNA interference
targeting the M2 subunit of ribonucleotide reductase: A novel
therapeutic strategy in pancreatic cancer. Surgery. 136:261–269.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujita H, Ohuchida K, Mizumoto K, Itaba S,
Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, et al:
Gene expression levels as predictive markers of outcome in
pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Neoplasia. 12:807–817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Souglakos J, Boukovinas I, Taron M, Mendez
P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A,
Stathopoulos E, Georgoulias V and Rosell R: Ribonucleotide
reductase subunits M1 and M2 mRNA expression levels and clinical
outcome of lung adenocarcinoma patients treated with
docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moorthy NS, Cerqueira NM, Ramos MJ and
Fernandes PA: Development of ribonucleotide reductase inhibitors: A
review on structure activity relationships. Mini Rev Med Chem.
13:1862–1872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerqueira NM, Pereira S, Fernandes PA and
Ramos MJ: Overview of ribonucleotide reductase inhibitors: An
appealing target in anti-tumour therapy. Curr Med Chem.
12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giannattasio M and Branzei D: S-phase
checkpoint regulations that preserve replication and chromosome
integrity upon dNTP depletion. Cell Mol Life Sci. 74:2361–2380.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dyawanapelly S, Kumar A and Chourasia MK:
Lessons learned from gemcitabine: Impact of therapeutic carrier
systems and Gemcitabine's drug conjugates on cancer therapy. Crit
Rev Ther Drug Carrier Syst. 34:63–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
